Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq:AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29 at 9:40 a.m. ET.
Related news for (AVIR)
- Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
- Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
- Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
- Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025